Xcout IntelMindWalk Holdings Corp.
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
Subscribe to see MindWalk Holdings Corp.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MindWalk Holdings Corp. at a glance
MindWalk Holdings Corp. is a holding company headquartered in Austin, United States. It is publicly listed (HYFT) with a market capitalisation of $71.6M. Xcout tracks 16 named people at MindWalk Holdings Corp., including Jennifer Lynne Bath (Chief Executive Officer, President & Non-Independent Director).
MindWalk Holdings Corp. leadership
- Jennifer Lynne BathChief Executive Officer, President & Non-Independent Director
- Dr. Jennifer Bath, PhDChief Executive Officer and President
- Richard Scott AregladoChief Financial Officer
- R. Scott AregladoChief Financial Officer
- Dirk Van HyfteChief Technology Officer
- Thomas LynchChief Business Officer
10 more named people on record for MindWalk Holdings Corp., with roles, board committees and tenure — see the full roster →
MindWalk Holdings Corp. competitors
A few of MindWalk Holdings Corp.'s closest competitors — see the full list of competitors and alternatives →
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder. Beyond its current commercial use, BXCL501 is also undergoing further clinical investigation. Studies are underway to assess its efficacy for agitation in individuals with Alzheimer's disease, as an add-on therapy for major depressive disorder, and for use in community settings to address agitation linked to bipolar disorders and schizophrenia. Furthermore, BioXcel is advancing BXCL502, a candidate therapy targeting chronic agitation prevalent in dementia patients. Another key pipeline asset is BXCL701, an orally administered systemic innate immunity activator currently under investigation. This compound shows promise for treating aggressive prostate cancer and advanced solid tumors that have either become resistant to checkpoint inhibitors or have not yet received such treatment. Established in 2017, the company maintains its headquarters in New Haven, Connecticut.
Variational AI is a privately held biotechnology startup headquartered in Vancouver, British Columbia. Founded in 2019, the company focuses on drug discovery, utilizing artificial intelligence to identify novel drug-like small molecules. Recognized as an innovative AI enterprise in Canada, it develops advanced computational methods for pharmaceutical research.
Psylinks Neurotech Corp develops advanced neurotechnology, including Omnia, a core data collection engine designed for near real-time AI applications in defense and intelligence. The company also tests low-channel EEG data collection in flight. Psylinks Neurotech Corp was acquired by Olenox Industries Inc. on July 3, 2026.
InspectMind AI is a privately held software company founded in 2024 and headquartered in San Francisco, California. With a small team of about 10 employees, the company develops AI-powered solutions for inspections and related industries.
BioReact is an artificial intelligence-driven biotechnology company headquartered in Indianapolis, Indiana. Founded to overcome barriers in bioprocess development, it provides bioprocess analytics software that integrates fragmented scientific data using SaaS and big data tools.
Get MindWalk Holdings Corp.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on MindWalk Holdings Corp. in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 4 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access